

## REMARKS


Reconsideration and allowance are respectfully requested.

Claims 32-49 were pending. In this response, claims 32-49 are cancelled without prejudice and new claims 50-70 are added. Support for the new claims can be found in the specification and claims as originally filed. For example, DNA constructs comprising SEQ ID NO:1 and SEQ ID NO:3 are disclosed at page 5, lines 27-32, and hybridization conditions are disclosed at page 4, lines 24-32. Endoglucanase-encoding sequences obtained using the primers recited in claim 56 are disclosed at pages 21-28. No new matter is added. Accordingly, claims 50-70 are pending and at issue.

Claims 32-49 have been rejected under 35 U.S.C. §112, first paragraph, for lack of enablement, based on the requirement for use of an antibody. Claims 41 and 44 have been rejected under 35 U.S.C. § 112, second paragraph, for indefiniteness. Claims 32-49 have been rejected under the judicially created doctrine of obviousness-type double patenting over the claims of U.S. Patent No. 5,948,672 (of which the present application is a continuation). Finally, claims 32-49 have been rejected under U.S.C. § 103(a) as unpatentable over Barbesgaard, U.S. Patent No. 4,435,307; Ortega, *Chem. Abst.* 114:619; and Janson, *Trends Biotechnol.* 2:31-38. It is respectfully submitted that these rejections are rendered moot by the cancellation of claims 32-49.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,



Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Date: December 7, 1999

B